Literature DB >> 19449407

Independent NF1 and PTPN11 mutations in a family with neurofibromatosis-Noonan syndrome.

Christian Thiel1, Martin Wilken, Martin Zenker, Heinrich Sticht, Raimund Fahsold, Gabriele-Charlotte Gusek-Schneider, Anita Rauch.   

Abstract

Neurofibromatosis-Noonan syndrome (NFNS), an entity which combines both features of Noonan syndrome (NS) and neurofibromatosis type 1 (NF1), was etiologically unresolved until recent reports demonstrated NF1 mutations in the majority of patients with NFNS. The phenotypic overlap was explained by the involvement of the Ras pathway in both disorders, and, accordingly, clustering of the NF1 mutations in the GTPase-activating protein (GAP) domain of neurofibromin was observed in individuals with NFNS. We report on an 18-month-old girl with typical findings suggestive of NS in combination with multiple café-au-lait spots and bilateral optic gliomas suggestive of NF1. The patient was found to carry a de novo PTPN11 mutation p.T2I as well as the maternally inherited NF1 mutation c.4661+1G>C. Her otherwise healthy mother and brother, who also had the NF1 mutation, showed few café-au-lait spots as the only sign of neurofibromatosis. Since our patient's unique NF1 mutation results in skipping of exon 27a and thus involves the same region, Gap-related domain, that had been shown to be associated with NFNS, her phenotype could have been misleadingly attributed to the NF1 mutation only. Contrarily, absence of both cutaneous neurofibromas and NS features in her relatives with the same NF1 mutation, suggests that the index patient's typical NFNS phenotype is caused by an additive effect of mutations in both NF1 and PTPN11. In contrast to previous findings, we speculate that absence of cutaneous neurofibromas is not solely associated with the recurrent 3-bp in-frame deletion in exon 17. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19449407     DOI: 10.1002/ajmg.a.32837

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  25 in total

1.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

Review 2.  RAS Proteins and Their Regulators in Human Disease.

Authors:  Dhirendra K Simanshu; Dwight V Nissley; Frank McCormick
Journal:  Cell       Date:  2017-06-29       Impact factor: 41.582

3.  LEOPARD syndrome (PTPN11, T468M) in three boys fulfilling neurofibromatosis type 1 clinical criteria.

Authors:  Atilano Carcavilla; Isabel Pinto; Rafael Muñoz-Pacheco; Raquel Barrio; Maria Martin-Frías; Begoña Ezquieta
Journal:  Eur J Pediatr       Date:  2011-03-02       Impact factor: 3.183

4.  Clinical and Molecular Findings of Tunisian Patients with RASopathies.

Authors:  Rim Louati; N Bouayed Abdelmoula; Imen Trabelsi; Dorra Abid; Christina Lissewski; Najla Kharrat; Samir Kamoun; Martin Zenker; Tarek Rebai
Journal:  Mol Syndromol       Date:  2014-05-23

Review 5.  RASopathy Gene Mutations in Melanoma.

Authors:  Ruth Halaban; Michael Krauthammer
Journal:  J Invest Dermatol       Date:  2016-05-25       Impact factor: 8.551

6.  SPRED 1 mutations in a neurofibromatosis clinic.

Authors:  Talia M Muram-Zborovski; David A Stevenson; David H Viskochil; David C Dries; Andrew R Wilson
Journal:  J Child Neurol       Date:  2010-02-22       Impact factor: 1.987

7.  A new nonsense mutation in the NF1 gene with neurofibromatosis-Noonan syndrome phenotype.

Authors:  Sevgi Yimenicioğlu; Ayten Yakut; Kadri Karaer; Martin Zenker; Arzu Ekici; Kürşat Bora Carman
Journal:  Childs Nerv Syst       Date:  2012-09-11       Impact factor: 1.475

8.  Increased rate of missense/in-frame mutations in individuals with NF1-related pulmonary stenosis: a novel genotype-phenotype correlation.

Authors:  Shay Ben-Shachar; Shlomi Constantini; Hen Hallevi; Emma K Sach; Meena Upadhyaya; Gareth D Evans; Susan M Huson
Journal:  Eur J Hum Genet       Date:  2012-10-10       Impact factor: 4.246

9.  Neurofibromatosis type 1 (NF1) associated with tumor of the corpus callosum.

Authors:  Ignacio Pascual-Castroviejo; Samuel-Ignacio Pascual-Pascual
Journal:  Childs Nerv Syst       Date:  2012-09-22       Impact factor: 1.475

10.  A rasopathy phenotype with severe congenital hypertrophic obstructive cardiomyopathy associated with a PTPN11 mutation and a novel variant in SOS1.

Authors:  Jill A Fahrner; Aisha Frazier; Suha Bachir; Michael F Walsh; Carolyn D Applegate; Reid Thompson; Marc K Halushka; Anne M Murphy; Meral Gunay-Aygun
Journal:  Am J Med Genet A       Date:  2012-05-14       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.